SSSara Elizabeth Stinson

Sara Elizabeth Stinson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sara Elizabeth Stinson has a total of 386 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multi-ancestry, trans-generational GWAS meta-analysis of gestational diabetes and glycaemic traits during pregnancy reveals limited evidence of pregnancy-specific genetic effects

    by Caroline Brito Nunes, Valentina Rukins, Aminata H. Cisse, Frédérique White, Nancy McBride, Alan Kuang, Catherine Allard, Justiina Ronkainen, Alice Hughes, Amanda Elliott, et al.

    Gestational diabetes mellitus (GDM) affects ~14% of pregnancies and increases maternal type 2 diabetes mellitus (T2DM) risk. The GenDiP Consortium presents trans-generational, multi-ancestry genome-wide association study meta-analyses of GDM and pregnancy glycemic traits in up to 38,305 GDM cases and 776,145 controls. We identify 37 GDM-associated loci (7 novel) and five novel loci for pregnancy glycemic traits, all operating through the maternal genome. We classify 12 GDM variants with stronger effects in GDM than T2DM into five biologically informed categories, revealing pleiotropy patterns, pregnancy-dependent effect modification, and diagnostic heterogeneity. While all these loci overlap with T2DM and/or non-pregnant glycaemic traits, four (G6PC2, CAST-PCSK1, HKDC1, FOXA2) lack genome-wide-significant T2DM associations; GCK shows distinct causal variants for GDM, and MTNR1B exhibits pregnancy-amplified effects. Our findings provide new genetic insights into GDM and highlight the need for larger, ancestrally diverse studies of GDM and glycaemic traits during pregnancy to understand potential pregnancy-specific effects.


  • Open Access

    Sex differences in genetic pathways underlying ischaemic heart disease–depression comorbidity

    by Cato Romero, Alexey A. Shadrin, Nadine Parker, Sara E. Stinson, Linn Rødevand, Dennis van der Meer, Kevin S. O’COnnell, Eva van Walree, Jeanne E. Savage, Danielle Posthuma, et al.

    Background and Aims: Comorbidity between ischaemic heart disease (IHD) and depression (DEP) is prevalent and more pronounced in woman than in men. The biological basis of these sex differences, however, remains unclear. We aimed to assess the contribution of genetic and biological risk factors to sex differences in IHD–DEP comorbidity. Methods: We analysed sex-stratified genome-wide association study summary statistics from 1.14 million individuals of European ancestry across multiple large-scale cohorts and international consortia. Global and local genetic correlations ( r g ), pleiotropic loci, and IHD-DEP shared genes were identified using LDSC, MiXeR, LAVA, conjunctional FDR, and FLAMES. We conducted conditional analyses using genetic and phenotypic data for 331 putative risk factors. Results: The r g between IHD and DEP was twice as high in females ( r g =.43) compared to males ( r g =.21), explaining a greater proportion of comorbidity in females (21% vs 13%). Pleiotropy analyses identified sex-specific genomic regions and genes contributing to IHD–DEP comorbidity. Genetic conditional analysis indicated that behavioural traits (alcohol use, insomnia, social deprivation) contributed more to male IHD–DEP comorbidity, whereas asthma and female-specific health traits contributed more to female IHD–DEP comorbidity. Phenotypic mediation largely reflected the same pattern. Conclusions: Higher IHD-DEP comorbidity in females compared to males is partly attributable to greater shared genetic liability. Distinct genes and differing contributions of behavioural, metabolic, immunological, and reproductive factors further shape these sex differences. These results support sex-aware risk stratification—targeting alcohol, sleep, and loneliness in males and endocrine status and asthma control in females.

  • Open Access

    Distinct metabolic signatures of Alzheimer's and Parkinson's disease revealed through genetic overlap

    by Sara E. Stinson, Alexey A. Shadrin, Zillur Rahman, Linn Rødevand, Iris J. Broce, Geir Selbæk, Hreinn Stefansson, Jan Haavik, Nadine Parker, Elise Koch, et al.


  • Open Access

    Identification of modifiable plasma protein markers of cardiometabolic risk in children and adolescents with obesity

    by Sara Elizabeth Stinson, Yun Huang, Roman Thielemann, Evelina Stankevic, Morten Asp Vonsild Lund, Louise Aas Holm, Cilius Esmann Fonvig, Helene Bæk Juel, Dmitrii Borisevich, Maja Thiele, et al.

    Pediatric obesity is linked to multi-organ inflammation and an increased risk of cardiometabolic and steatotic liver disease. To identify circulating biomarkers of cardiometabolic risk, we performed proximity extension assay proteomics, to quantify 149 inflammation- and cardiovascular-related proteins in a cross-sectional study of 4024 children and adolescents (2377 with obesity and 1647 with normal weight). We identified protein signatures linked to obesity, dyslipidemia, insulin resistance, hyperglycemia, hypertension, and related cardiometabolic phenotypes. Using machine learning, a three-protein panel (CDCP1, FGF21, HAOX1) combined with liver enzymes improved prediction of steatotic liver disease versus liver enzymes alone (receiver operating characteristic–area under the curve (ROC–AUC) = 0.83 vs. 0.77; DeLong’s test, P < 0.05). During a 1-year non-pharmacological obesity intervention (n = 184), reductions in adiposity were associated with decreased inflammatory cytokines (including CDCP1, FGF21), which correlated with improvements in cardiometabolic risk profiles. Here we show that circulating proteomic signatures may mediate obesity-related cardiometabolic risk in youth.


  • Genetic regulation of the plasma proteome and its link to cardiometabolic disease in Greenlandic Inuit

    by Sara E. Stinson, Renzo F. Balboa, Mette K. Andersen, Frederik F. Stæger, Shixu He, Anne Cathrine Baun Thuesen, Long Lin, Emil Jørsboe, Peter Bjerregaard, Christina V.L. Larsen, et al.


  • Open Access

    Distinct metabolic signatures of Alzheimer’s and Parkinson’s disease revealed through genetic overlap with metabolic markers

    by Sara Elizabeth Stinson, Alexey A. Shadrin, Zilur Rahman, Linn Rødevand, Iris J. Broce, Karin Persson, Geir Selbæk, Hreinn Stefansson, Jan Haavik, Nadine Parker, et al.

    Metabolic dysfunction is increasingly implicated in neurodegenerative diseases, yet the genetic architecture linking metabolic markers with Alzheimer’s disease (AD) and Parkinson’s disease (PD) remains unclear. We systematically analysed phenotypic and genetic relationships between 249 circulating metabolites with AD and PD, comparing patterns to body mass index (BMI), type 2 diabetes (T2D), coronary artery disease (CAD) and stroke. Using linkage disequilibrium score regression and bivariate Gaussian mixture modeling, we identified distinct genetic overlap. AD correlated positively with cardiometabolic traits (BMI, r s =0.11; T2D, r s =0.23; CAD, r s =0.22; stroke, r s =0.18), whereas PD showed opposing patterns (AD–PD r s =−0.36). Mendelian randomization identified bi-directional causal effects of lipid measures on AD and divergent effects of glutamine on AD and PD. Conjunctional FDR analyses mapped 1,377 shared genes, implicating lipid metabolism in AD and synaptic processes in PD. These findings disentangle disease-specific pathways and inform therapeutic strategies targeting metabolic health.


  • Open Access

    Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community

    by Camilla Dalby Hansen, Johanne Kragh Hansen, Mads Israelsen, Peter Andersen, Laura Maarit Pikkupeura, Katrine Prier Lindvig, Sara Elizabeth Stinson, Helle Lindholm Schnefeld, Julie Tellerup, Maria Fogt, et al.


  • Open Access

    The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial

    by Johanne K. Hansen, Mads Israelsen, Suguru Nishijima, Sara E. Stinson, Peter Andersen, Stine Johansen, Camilla D. Hansen, Maximilian Joseph Brol, Sabine Klein, Robert Schierwagen, et al.

    Impaired gut barrier function may lead to progression of liver fibrosis in people with alcohol-related liver disease. The postbiotic ReFerm® can lower gut barrier permeability and may thereby reduce fibrosis formation. Here, we report the results from an open-labelled, single centre randomized controlled trial where 56 patients with advanced, compensated, alcohol-related liver disease were assigned 1:1 to receive either ReFerm® (n = 28) or standard nutritional support (Fresubin®, n = 28) for 24 weeks. The primary outcome was a ≥ 10% reduction of the fibrosis formation marker alpha-smooth muscle actin in liver biopsies, assessed by a blinded pathologist using automated digital imaging analysis. Paired liver biopsies meeting quality criteria for the primary outcome were available for 40 participants (ReFerm®, n = 21 and Fresubin®, n = 19). This reduction was observed in 29% of patients receiving ReFerm®, compared to 14% with Fresubin® (OR = 2.40; 95% CI 0.63 to 9.16; p = 0.200). No treatment-related serious adverse events occurred. Our findings suggest that ReFerm® may reduce liver fibrosis by enhancing gut barrier function, potentially preventing the progression of alcohol-related liver disease.


  • Open Access

    Pleiotropic and sex-specific genetic mechanisms of circulating metabolic markers

    by Dennis van der Meer, Zillur Rahman, Aigar Ottas, Pravesh Parekh, Gleda Kutrolli, Sara E. Stinson, Maria Koromina, Jaroslav Rokicki, Ida E. Sønderby, Nadine Parker, et al.

    Metabolites in plasma form biosignatures of a range of common complex human diseases. Discovering variants with pleiotropic effects across metabolites can reveal underlying biological mechanisms. We therefore performed uni- and multivariate genome-wide association studies (GWAS) on 249 circulating metabolic markers across 328,006 UK Biobank and Estonian Biobank participants. We investigated rare variation through whole exome sequencing gene burden tests, analysed the role of body mass index through Mendelian randomization, and performed genome-wide interaction analyses with sex. We discovered 15,585 loci summed over the univariate GWAS, with high pleiotropy across markers, linked to a wide range of disorders. Findings from common and rare variant gene tests converged on lipid homeostasis pathways. 31 loci interacted with sex, mapped to genes involved in cholesterol processing. The findings offer insights into the genetic architecture of circulating metabolites, revealing pleiotropic loci, highlighting the role of rare variation, and uncovering sex-specific molecular mechanisms of lipid metabolism.